Ipragliflozin is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used in type 2 diabetes treatment. It lowers blood glucose by promoting urinary glucose excretion, which also leads to reduced body weight and lowers the risk of hypoglycemia. It is grouped under the following drug class(es): Hypoglycemics and SGLT2 inhibitors. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include ipragliflozina and ipragliflozine. Its PubChem CID is 10453870.
Ipragliflozin
| CAS No | 761423-87-4 |
|---|---|
| Molecular Formula | C21H21FO5S |
| Molecular Weight | 404.5 g/mol |
| Synonyms | (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ipragliflozin is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used in type 2 diabetes treatment. It lowers blood glucose by promoting urinary glucose excretion, which also leads to reduced body weight and lowers the risk of hypoglycemia.
The listed CAS number is 761423-87-4.
The listed molecular formula is C21H21FO5S.
The listed molecular weight is 404.5 g/mol.
(2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol.
The source lists ipragliflozina and ipragliflozine.